Herbert A. Eradat, MD, MS
University of California, Los Angeles
2009
$
25000
Tower Career Development Grant
Defining the Molecular Correlates that Determine Activity of Pan-PIM Inhibitor, SGI-1776
PIM kinases are oncogenes that are known to cause lymphomas. Our laboratory was the first to show that PIM-1 predicts shorter survival in aggressive lymphomas and we are currently conducting the first trial of a pill that inactivates PIM kinases. The core of this grant proposal is defining the molecular characteristics that will determine the activity of the PIM inhibitor SGI-1776 in lymphomas. In addition, we will test another target (cyclin D1) for its ability to collaborate with PIM kinases in causing lymphomas. This research may lay the foundation of novel combination treatment strategies.
Support the Journey
When you donate to Tower, you’re not supporting a single study. You’re part of an ecosystem that believes the next breakthrough is out there, waiting for someone to believe in it first. Every gift puts resources directly behind the discoveries that would otherwise never see the light of day.